Cargando…

Dalbavancin dosage adjustments not required for patients with mild to moderate renal impairment

Detalles Bibliográficos
Autores principales:	Dowell, J, Seltzer, E, Stogniew, M, Dorr, MB, Fayocavitz, S, Krause, D, Henkel, T, Marbury, T, Simoneau, D, Boudry, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088397/ http://dx.doi.org/10.1186/cc6247

Ejemplares similares

The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
por: Dowell, J, et al.
Publicado: (2008)

Dalbavancin safety in the phase 2/3 clinical development program
por: Seltzer, E, et al.
Publicado: (2008)

The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa
por: Molinelli, Elisa, et al.
Publicado: (2022)

Predicted Vancomycin Dosage Requirement in Patients With Hematological Malignancies and Dosage Dynamic Adjustment
por: Song, Xiangqing, et al.
Publicado: (2022)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
por: Seltzer, Ben
Publicado: (2010)

Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam
por: Kletzl, Heidemarie, et al.
Publicado: (2022)

Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment
por: Dowell, James A., et al.
Publicado: (2022)

Dalbavancin: a novel antimicrobial
por: Chen, A Y, et al.
Publicado: (2007)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
por: Tortorici, Michael A., et al.
Publicado: (2010)

Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin
por: Loupa, Chariclia V., et al.
Publicado: (2020)

The Rate of Antibiotic Dosage Adjustment in Renal Dysfunction
por: Fahimi, Fanak, et al.
Publicado: (2012)

The hidden cost of dalbavancin: OPAT RN time required in coordination for persons who use drugs
por: Douglass, Alyse H., et al.
Publicado: (2023)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

Dalbavancin: novel candidate for COVID-19 treatment
por: Hoffmann, Markus, et al.
Publicado: (2021)

Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2022)

Global trends of dalbavancin: A bibliometric analysis
por: Monteagudo‐Martínez, Nuria, et al.
Publicado: (2022)

Dalbavancin for Staphylococcus aureus Bacteremia: Are We There Yet?
por: Mahatanan, Rattanaporn, et al.
Publicado: (2023)

2902. Dalbavancin Use in Bone and Joint Infections
por: Sanikommu, Srivani, et al.
Publicado: (2023)

2764. Experience with dalbavancin in a pediatric hospital
por: Leon, Maria Deza, et al.
Publicado: (2023)

Dalbavancin Use for the Treatment of Methicillin-resistant Staphylococcus aureus Pneumonia
por: Barber, Katie E., et al.
Publicado: (2017)

Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension
por: Smith, William B., et al.
Publicado: (2012)

Tylosin Dosage Adjustment Based on Allometric Scaling in Male Turkeys
por: Poźniak, Błażej, et al.
Publicado: (2021)

Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis
por: Carrothers, Timothy J., et al.
Publicado: (2019)

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

122. Dalbavancin Use in Patients with Substance Use Disorders
por: Streifel, Amber C, et al.
Publicado: (2020)

Use of dalbavancin in infective endocarditis: a case series
por: Guleri, Achyut, et al.
Publicado: (2021)

614. Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2021)

1004. Dalbavancin Use and Associated Cost-Savings: An Update
por: Streifel, Amber C, et al.
Publicado: (2022)

Dalbavancin in Bone and Joint Infections: A Systematic Review
por: Lovatti, Sofia, et al.
Publicado: (2023)

1318. Pharmacokinetics and Safety of Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) in Subjects with Renal Impairment
por: Geibel, Brooke, et al.
Publicado: (2020)

Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments
por: Pauley, Jennifer L., et al.
Publicado: (2013)

Pharmacokinetics of Vancomycin in Oncology Egyptian Paediatrics: A Dosage Adjustment Trial
por: Mahmoud, M. A., et al.
Publicado: (2014)

Assessment of Medication Dosage Adjustment in Hospitalized Patients With Chronic Kidney Disease
por: Hassan, Zair, et al.
Publicado: (2021)

Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin
por: Cheng, Mu, et al.
Publicado: (2014)

In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile
por: Binyamin, Dana, et al.
Publicado: (2018)

Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care
por: Ajaka, Leama, et al.
Publicado: (2020)

438. Dalbavancin Clinical Experience at an NCI Designated Cancer Center
por: McDaneld, Patrick, et al.
Publicado: (2019)

1028. Dalbavancin Use in Complicated Infections and-associated Cost-Savings
por: Streifel, Amber C, et al.
Publicado: (2019)

Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization
por: Simonetti, Oriana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8a8pii5082mcgj4so5p3jlkbbc